Cargando…

Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy

Aims: To construct a predictive model for overall survival (OS) in unresectable pancreatic cancer (PaC) undergoing systemic chemotherapy and to confirm its accuracy in an independent cohort. Patients and methods: The training set (Ts) and the validation set (Vs) included 93 patients (median age=71 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Noriko, Nishikawa, Hiroki, Iwata, Yoshinori, Enomoto, Hirayuki, Tanaka, Hironori, Katakami, Nobuyuki, Nishimura, Takashi, Iijima, Hiroko, Nishiguchi, Shuhei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959067/
https://www.ncbi.nlm.nih.gov/pubmed/31956368
http://dx.doi.org/10.7150/jca.38861
_version_ 1783487527883112448
author Ishii, Noriko
Nishikawa, Hiroki
Iwata, Yoshinori
Enomoto, Hirayuki
Tanaka, Hironori
Katakami, Nobuyuki
Nishimura, Takashi
Iijima, Hiroko
Nishiguchi, Shuhei
author_facet Ishii, Noriko
Nishikawa, Hiroki
Iwata, Yoshinori
Enomoto, Hirayuki
Tanaka, Hironori
Katakami, Nobuyuki
Nishimura, Takashi
Iijima, Hiroko
Nishiguchi, Shuhei
author_sort Ishii, Noriko
collection PubMed
description Aims: To construct a predictive model for overall survival (OS) in unresectable pancreatic cancer (PaC) undergoing systemic chemotherapy and to confirm its accuracy in an independent cohort. Patients and methods: The training set (Ts) and the validation set (Vs) included 93 patients (median age=71 years) and 75 patients (median age=76 years). In the Ts, we examined variables linked to OS by uni- and multivariate analyses and constructed a predictive model for OS. Next, we evaluated the reproducibility of the proposed model in the Vs. Results: In the multivariate analysis for the Ts, PaC stage IV (P=0.0020) and carbohydrate antigen (CA) 19-9 ≥437.5 IU/l (P=0.0237) were identified to be significant factors associated with OS. Patients with PaC stage IV or not were given a score of 1 or 0, whereas patients with CA19-9 ≥437.5 IU/l or <437.5 IU/l were given a score of 1 or 0. Sum of the point of PaC stage (0 or 1) and CA19-9 (0 or 1) was defined as “PaC-CA score”. In the Ts, there were 16 patients with score 0, 40 with score 1 and 37 with score 2, while in the Vs, there were 9 patients with score 0, 32 with score 1 and 34 with score 2. Overall P values reached significance in the Ts (P=0.0002), the Vs (P=0.0029) and the combined Ts and Vs (P<0.0001) among patients with PaC score 0, 1 and 2. Conclusion: PaC-CA score can be helpful for risk stratification in PaC patients undergoing systemic chemotherapy.
format Online
Article
Text
id pubmed-6959067
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-69590672020-01-18 Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy Ishii, Noriko Nishikawa, Hiroki Iwata, Yoshinori Enomoto, Hirayuki Tanaka, Hironori Katakami, Nobuyuki Nishimura, Takashi Iijima, Hiroko Nishiguchi, Shuhei J Cancer Research Paper Aims: To construct a predictive model for overall survival (OS) in unresectable pancreatic cancer (PaC) undergoing systemic chemotherapy and to confirm its accuracy in an independent cohort. Patients and methods: The training set (Ts) and the validation set (Vs) included 93 patients (median age=71 years) and 75 patients (median age=76 years). In the Ts, we examined variables linked to OS by uni- and multivariate analyses and constructed a predictive model for OS. Next, we evaluated the reproducibility of the proposed model in the Vs. Results: In the multivariate analysis for the Ts, PaC stage IV (P=0.0020) and carbohydrate antigen (CA) 19-9 ≥437.5 IU/l (P=0.0237) were identified to be significant factors associated with OS. Patients with PaC stage IV or not were given a score of 1 or 0, whereas patients with CA19-9 ≥437.5 IU/l or <437.5 IU/l were given a score of 1 or 0. Sum of the point of PaC stage (0 or 1) and CA19-9 (0 or 1) was defined as “PaC-CA score”. In the Ts, there were 16 patients with score 0, 40 with score 1 and 37 with score 2, while in the Vs, there were 9 patients with score 0, 32 with score 1 and 34 with score 2. Overall P values reached significance in the Ts (P=0.0002), the Vs (P=0.0029) and the combined Ts and Vs (P<0.0001) among patients with PaC score 0, 1 and 2. Conclusion: PaC-CA score can be helpful for risk stratification in PaC patients undergoing systemic chemotherapy. Ivyspring International Publisher 2020-01-01 /pmc/articles/PMC6959067/ /pubmed/31956368 http://dx.doi.org/10.7150/jca.38861 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Ishii, Noriko
Nishikawa, Hiroki
Iwata, Yoshinori
Enomoto, Hirayuki
Tanaka, Hironori
Katakami, Nobuyuki
Nishimura, Takashi
Iijima, Hiroko
Nishiguchi, Shuhei
Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title_full Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title_fullStr Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title_full_unstemmed Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title_short Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
title_sort proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959067/
https://www.ncbi.nlm.nih.gov/pubmed/31956368
http://dx.doi.org/10.7150/jca.38861
work_keys_str_mv AT ishiinoriko proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT nishikawahiroki proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT iwatayoshinori proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT enomotohirayuki proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT tanakahironori proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT katakaminobuyuki proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT nishimuratakashi proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT iijimahiroko proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy
AT nishiguchishuhei proposalofpredictivemodelonsurvivalinunresectablepancreaticcancerreceivingsystemicchemotherapy